TriVisc

TriVisc is supplied as a sterile, non-pyrogenic solution in 3mL pre-filled syringe.

Reimbursement Code J7329

With TriVisc comes HARMOKNEE®, our comprehensive customer support services. Patients can purchase TriVisc directly and save money, while you retain control over the process. The TriVisc Direct Purchase Program is designed for patients without an HA insurance benefit, or those who choose not to use insurance to pay for HA treatments. TriVisc can be purchased with a prescription directly from our partner pharmacy network, then shipped to your practice for scheduling and administering the treatments. Enrolling a patient in our Direct Purchase Program is easy. To learn about program eligibility and getting started, visit triviscdpp.com or call us at 866-556-2259

TriVisc is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics (eg, acetaminophen).

TriVisc is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of present infections or skin diseases in the area of the injection site to reduce the potential for developing septic arthritis.

• Do not concomitantly use disinfectants containing quaternary ammonium salts for skin preparation because sodium hyaluronate can precipitate in their presence.
• Remove joint effusion, if present, before injecting TriVisc.
• Do not use TriVisc if the package is opened or damaged. Store in the original packaging (protected from light) below 86°F (30°C). DO NOT FREEZE. Do not use after expiration date indicated on package. The shelf life of TriVisc is 42 months.
• The effectiveness of a single treatment cycle of less than 3 injections has not been established.
• Transient increases in inflammation following any intra-articular hyaluronan injection have been reported in some patients with inflammatory joint conditions.
• The effectiveness of repeat treatment cycles of TriVisc has not been established.
• Strict aseptic administration technique must be followed to avoid infections in the injection site.
• The safety and effectiveness of the use of TriVisc in joints other than the knee have not been established.
• The safety and effectiveness of the use of TriVisc concomitantly with other intraarticular injectable products have not been established.

The most commonly reported adverse events in the TriVisc group included injection site pain⁶, allergic reaction³, arthralgia², and bleeding at the injection site.²

<sup>References
1. TriVisc Package Insert
2. FDA summary of safety and effectiveness data (SSED). TriVisc®
3. https://clinicaltrials.gov/ct2/show/results/NCT02110238? term=Supartz&view=results
4. Uluçay C, Altintaş F, Ugutmen E, Beksaç B. The use of arthroscopic debridement and viscosupplementation in knee osteoarthritis. Acta Orthop Traumatol Turc. 2007;41: 337-342.
5. Dıraçoğlu D,  Tunçay TB, Şahbaz T, Aksoy C. Single versus multiple dose hyaluronic acid: Comparison of the results. J Back Musculo Rehab. 2016; 29(4):881–86.
6. ÖzgÖnenel L, et al. Comparison of different hyaluronates. Istanbul Tıp Dergisi 2008:1 ;53-57.</sup>